Ken Griffin Moon Lake Immunotherapeutics Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Citadel Advisors LLC holds 30,200 shares of MLTX stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,200
Previous 25,600
17.97%
Holding current value
$1.23 Million
Previous $1.55 Million
1.88%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding MLTX
# of Institutions
135Shares Held
56MCall Options Held
379KPut Options Held
402K-
Bvf Inc San Francisco, CA21.8MShares$884 Million32.73% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$345 Million24.56% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.58MShares$105 Million1.56% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.28MShares$92.9 Million0.23% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.14MShares$86.8 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.5B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...